A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
Part of paid clinical trials in San Diego, California.
- Sponsor
- Rocket Pharmaceuticals Inc.
- Study ID
- NCT07137338
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Dilated Cardiomyopathy (DCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) — GENETICOne-time treatment with a single ascending dose
Study Details
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- May 2026
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 8 participants (estimated)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Single ascending dose of RP-A701 in up to 2 consecutive cohortsParticipants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years
Primary Outcome Measure
Incidence of Treatment-emergent Adverse Events (TEAE) [ Time Frame: Baseline up to End of Study (up to 24 months post-infusion) ]
Central Contacts
- Clinical Information646-627-0033
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Diego | San Diego | California | 92037 | Barry Greenberg, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic | Rochester | Minnesota | 55905 | John Giudicessi, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Daniel Judge, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Diego, CA
Related Studies
- Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac ArrhythmiasEnrolling By Invitation · Johns Hopkins University · Baltimore, Maryland
- UIC Multi-Ethnic DCM RegistryRecruiting · University of Illinois at Chicago · Chicago, Illinois
- Study of the Progression of Chronic Cardiovascular ConditionsRecruiting · Prolaio · Chicago, Illinois
- An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)PHASE1/PHASE2 · Not Yet Recruiting · Affinia Therapeutics · Houston, Texas